At 90 minutes after application, Systane Ultra users maintained BCVA for 9.17±0.0365 seconds compared to 6.84±0.0365 seconds of maintained BCVA in Refresh Optive users If you’re using a bottle, remove the lid. If you’re using the single-dose dropper, twist the top off.

Make sure the tip of the bottle or dropper does not touch anything, including your eye, eyelashes, eyelid or your skin. Usually, drops may be used as often as needed. Ointments are usually used 1 to 2 times daily as needed. If using an ointment once a day, it may be best to use it at bedtime. Grey / Non-Formulary (undergoing assessment): Work is ongoing and will be reviewed at a future APC meeting. If you also use an eye ointment, always use your eye drops first and wait 5 minutes before using the ointment. Approved in accordance with the Clinical Commissioning Policy Statement for the treatment of severe ocular surface disease (all ages)

It is considered appropriate for Independent Prescribing Optometrists to prescribe or recommend prescribing of any licensed Green or Amber traffic light medicines within this Chapter of the formulary that are also within their recognised area of expertise and competence. The following additional adverse reactions have been identified during postmarketing use of Celluvisc in clinical practice. Because postmarketing reporting of these reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions. After 14 days of daily therapy, Systane-treated patients exhibited decreased conjunctival staining and diminished temporal corneal staining compared to patients treated with Refresh Tears If you find it hard to use eye drops, ask a pharmacist for advice. They may be able to recommend an eye drop dispenser. Using eye drops correctly can be difficult, but there are several useful devices (compliance aids) available to help. Speak to your pharmacist to see which device would best suit your eye drops. Brands include,Autodrop, Opticare and Drop Aid Single Dose. Expiry dates and storage Thuốc có thể được dùng như một chất bảo vệ tránh kích ứng mắt thêm nữa. 4.2. Liều dùng – Cách dùng:

Another randomized controlled study analyzing lipid-based tear substitutes looked at their effect on TBUT, Schirmer’s test, tear meniscus, and subjective symptoms. 49 This crossover study compared Tears Again ® (OcuSoft, Rosenberg, TX, USA) to Liposic ® (Bausch & Lomb) in 74 patients with a history of dry eye over two separate 6-week periods. In both the initial treatment and after cross-over, Tears Again ® improved all the aforementioned subjective and objective endpoints ( P<0.05); 62.5% of patients preferred Tears Again ®, 25% preferred Liposic ®, and 12.5% found the preparations to be equal. Dysfunctional tear syndrome (DTS), commonly known as dry eye syndrome, describes the multifactorial condition where the ocular system fails to produce good quality tears or a sufficient amount of tears to keep the eye moisturized. 1 Human tears, composed of electrolytes, water, proteins (eg, antibodies, lysozymes), and lipids, function to moisturize the ocular surface and minimize damage to the corneal epithelium. These components come together to form three distinct layers: 1) the outermost lipid layer, 2) a middle aqueous layer, and 3) the epithelium-covering mucoid layer. Dysfunction in any of these layers can yield tear film instability and hyperosmolarity. 2 , 3 External causes of such dysfunction are widespread including environmental factors, systemic diseases, and medications. 4 – 12

INDIA’S LARGEST HEALTHCARE PLATFORM

For use in patients with evaporative dry eye associated with moderate to severe meibomian gland disease. At 5, 10, 15, 20, and 60 minutes after application, Systane significantly prolonged tear break-up time compared to either Refresh therapies This study involved a review of the literature analyzing artificial tear treatments of DTS. The resources utilized were the electronic databases Medline (PubMed; http://www.ncbi.nlm.nih.gov), National Institutes of Health (NIH) clinical trials ( http://clinicaltrials.gov), Google Scholar, and the Cochrane Library. Keywords used in the search included dry eye, dysfunctional tear syndrome, Actimist, Advance Eye Relief, Akorn, Akwa, Blink, Clarymist, Clear Eyes, Freshkote, GenTeal, Hylogel, Isopto, Just Tears, Lacril, Lacrisert, Liposic, Lubrifresh, Murine Tears, Natural Balance, Nature’s Tears, Nutratear, Oasis Tears, Paralube, Refresh, Rohto Hydra, Systane, Soothe, Tearisol, Tears Again, Tears Natural, Thera Tears, Ultra Tears, Visco Tears, and Vizulize Dry Eye Mist. Both published articles and data from clinical trials (including multicenter, blinded studies as well as open label, industry-funded studies) were included in this study. Studies were excluded if the brand and specific type of artificial tear could not be identified. Data from unpublished clinical trials and articles from artificial tears that are no longer being produced were excluded. No other exclusion criteria were applied.

Medicines suitable to be prescribed in primary care / general practice after specialist* recommendation or initiation. Close your eye. Gently press your finger over the inside corner of your eye (over the eyelid) for about 1 minute. This helps to keep the drop in your eye. In an industry-sponsored, Alcon, head-to-head clinical trial, visual acuity was measured after application of Systane ® Ultra and Refresh Optive ®.36 The study population included 48 patients with a history of dry eye. Each patient underwent visual acuity evaluation while completing a computer task at 15, 45, and 90 minutes postapplication. The amount of time the patients maintained their best-corrected visual acuity was the measured end point. At 90 minutes, the mean time best-corrected visual acuity was maintained for 9.17 seconds with Systane versus 6.84 seconds with Refresh. These data were not statistically analyzed.The first study compared Systane ® (Alcon Laboratories, Inc., Fort Worth, TX, USA) to Refresh Tears ® (Allergan, Irvine, CA, USA) in 87 patients with dry eyes over a 6-week period. 37 Both investigators and patients were blinded to the artificial tear being used. The study evaluated the conjunctival/corneal staining and a custom symptom questionnaire at days 7, 14, 28, and 42. At days 14 and 28, patients using Systane ® showed significantly improved conjunctival staining compared to patients using Refresh Tears ®. At days 14 and 42, patients using Systane also had significantly decreased temporal corneal staining compared to patients using Refresh. Furthermore, subjective symptomatic improvement was significantly increased in patients using Systane when compared to those using Refresh.